AbbVie Inc. EV/FCF

EV/FCF of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/FCF of AbbVie Inc. is 12.37 (as of December 30, 2019)
  • EV/FCF for the quarter ending June 29, 2020 was 17.22 (a 68.23% increase compared to previous quarter)
  • Year-over-year quarterly EV/FCF increased by 59.17%
  • Annual EV/FCF for 2019 was 12.37 (a -9.28% decrease from previous year)
  • Annual EV/FCF for 2018 was 13.63 (a -30.38% decrease from previous year)
  • Annual EV/FCF for 2017 was 19.58 (a -2.41% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of AbbVie Inc.

Most recent EV/FCFof ABBV including historical data for past 10 years.

Interactive Chart of EV/FCF of AbbVie Inc.

AbbVie Inc. EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 17.22 10.24
2019 12.37 10.82 11.0 11.5 12.37
2018 13.63 14.7 16.57 17.42 13.63
2017 19.58 20.41 21.9 20.54 19.58
2016 20.06 19.03 17.07 15.27 20.06
2015 17.07 25.32 32.66 25.89 17.07
2014 37.79 20.28 19.59 16.9 37.79
2013 15.36 13.81 11.77 12.83 15.36
2012 10.49 10.49 10.49 10.49 10.49
2011 10.49 10.49 10.49 10.49 10.49
2010 10.49
2009 10.49

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.